A Study on the Efficacy and Safety of IPyC for HER2+ MBC

CompletedOBSERVATIONAL

Enrollment

301

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

August 1, 2024

Study Completion Date

May 1, 2025

Conditions

Breast Cancer

Interventions

DRUG

Inetetamab and Pyrotinib Combined with Chemotherapy

Trial Locations (1)

Fujian Cancer Hospital, Fuzhou

All Listed Sponsors

lead

Fujian Medical University

OTHER

NCT06990347 - A Study on the Efficacy and Safety of IPyC for HER2+ MBC | Biotech Hunter | Biotech Hunter